<DOC>
	<DOCNO>NCT00004868</DOCNO>
	<brief_summary>RATIONALE : SU5416 may stop growth astrocytoma glioma stop blood flow tumor . PURPOSE : Phase I/II trial study effectiveness SU5416 treat patient recurrent astrocytoma mixed glioma respond previous radiation therapy .</brief_summary>
	<brief_title>SU5416 Treating Patients With Recurrent Astrocytoma Mixed Glioma That Has Not Responded Radiation Therapy</brief_title>
	<detailed_description>OBJECTIVES : Phase I : - Determine maximum tolerate dose SU5416 patient recurrent malignant glioma , well , take enzyme-inducing antiepileptic drug . - Determine toxic effect ( safety profile ) drug patient population . - Characterize pharmacokinetics drug patient . - Develop exploratory data relative surrogate endpoint angiogenic activity vivo , include functional imaging vitro assay endothelial cell inhibition serum angiogenic peptide . Phase II : - Determine efficacy SU5416 , term 6-month progression-free survival , patient recurrent high-grade glioma . - Determine , , safety profile phase II dose drug patient population . - Develop exploratory data relative surrogate endpoint angiogenic activity vivo include functional imaging vitro assay endothelial cell inhibition serum angiogenic peptide . OUTLINE : This dose-escalation , multicenter study . Patients stratify accord concurrent enzyme-inducing antiepileptic drug ( vs yes ) . Patients receive SU5416 IV day 1 4 weekly 4 week . Courses repeat every 4 week absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos SU5416 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient accrue phase II portion study . These patient receive SU5416 IV , phase I portion , appropriate MTD establish phase I . Patients follow survival . PROJECTED ACCRUAL : At least 30 patient accrued phase I dose-escalation portion study within 10 month . An additional 48 patient ( 32 glioblastoma multiforme 16 anaplastic glioma ) accrue phase II portion study within 6-8 month .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Semaxinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove supratentorial malignant primary glioma , include : Glioblastoma multiforme Anaplastic astrocytoma Anaplastic oligodendroglioma Anaplastic mix oligoastrocytoma Malignant astrocytoma otherwise specify Benign malignant meningioma , include brain spinal meningioma Patients meningioma exclude phase II portion study Must show unequivocal evidence tumor recurrence progression CT scan MRI Must fail prior radiotherapy Must prestudy contrast MRI contrast CT scan brain stable steroid dose within past 14 day Must stable ( unchanged ) dose steroid least 5 day scan Phase II : Must complete radiotherapy least 2 month prior enrollment PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : More 8 week Hematopoietic : WBC least 2,300/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 8 g/dL ( transfusion allow ) Hepatic : SGOT le 2.5 time upper limit normal Bilirubin normal No significant active hepatic disease Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance least 60 mL/min No significant active renal disease Cardiovascular : No uncompensated coronary artery disease ECG physical examination No history myocardial infarction severe/unstable angina within past 6 month No deep venous arterial thrombosis within past 3 month Pulmonary : No pulmonary embolism within past 3 month Other : Not pregnant nursing Fertile patient must use effective contraception 2 month study No serious concurrent illness No significant active psychiatric disease No diabetes mellitus severe peripheral vascular disease No malignancy within past 3 year except nonmelanoma skin cancer carcinoma situ cervix No serious active infection No concurrent disease would obscure toxic effect dangerously alter drug metabolism PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior biologic therapy ( e.g. , interferon ) recover No concurrent immunotherapy Chemotherapy : Phase I : No 2 prior chemotherapy regimens recurrent disease Phase II : No 1 prior chemotherapy regimen recurrent disease At least 2 week since prior vincristine At least 6 week since prior nitrosoureas At least 3 week since prior procarbazine Recovered prior chemotherapy No concurrent chemotherapy Endocrine therapy : See Disease Characteristics At least 3 week since prior endocrine therapy ( e.g. , tamoxifen ) recover Radiotherapy : See Disease Characteristics No concurrent radiotherapy Surgery : Recovered prior surgery Recent prior resection recurrent progressive tumor allow Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult meningioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult grade III meningioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>